ArriVent License Pact for Antibody Drug Conjugate for Gastrointestinal Cancers

 

• Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers
• First Investigational New Drug (IND) submission planned for 1H 2025
• Expands ArriVent’s growing pipeline of next-generation ADCs

https://www.globenewswire.com/news-release/2025/01/22/3013133/0/en/ArriVent-BioPharma-Enters-Exclusive-License-with-Lepu-Biopharma-for-MRG007-an-Antibody-Drug-Conjugate-for-the-treatment-of-Gastrointestinal-Cancers.html